About GW

Which countries does GW carry out its research in?

GW is a UK-based company but its research network and operations stretches around the world. To date, GW has exported Sativex and other cannabinoid research materials to a total of 28 countries. The export of Sativex has been both for the purposes of supplying prescriptions as well as for use in clinical trials. The list of countries includes much of Europe, as well as the US and Canada, Australasia, South Africa and parts of Latin America

Does GW carry out research under special licences?

Yes. GW operates under licences granted by the UK Home Office. These licences allow the Group to research and develop cannabinoid prescription medications. GW’s products are being researched and prescribed in 22 countries around the world and the relevant governmental authority in each such country has granted GW the necessary controlled substance licences.

What are the aims of GW Pharmaceuticals?

GW aims to bring cannabinoid prescription medications to market in order to provide patients suffering from serious conditions with previously-unavailable treatment options which make a real difference to their quality of life. Through rapid cost-effective product development, addressing market needs, and establishing commercial partnerships, GW seeks to maximise the value of its products and shareholder returns. GW’s primary focus is in the field of cannabinoid science and in the research, development and commercialisation of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. GW's clinical research is initially focused on Multiple Sclerosis, cancer pain and neuropathic pain. The Company is also extending its research programme into new areas such as oncology, diabetes, epilepsy and psychiatric illness.

Where is GW located?

GW's head office is on the Porton Down Science Park near Salisbury in Wiltshire. The Group also has other offices in Cambridgeshire and London.

How many staff does GW have?

GW has approximately 130 employees.

What is GW Pharmaceuticals?

GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines , including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications

GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.

When was GW established?

The Group was founded in early 1998 and was first granted licenses by the Home Office in June 1998 to research and develop cannabinoid prescription medications.